Better Health for All

Viatris was part of a nationwide settlement to resolve claims that it fueled an opioid addiction epidemic, agreeing to pay up to $335 million over nine years towards state and local opioid initiatives

. Despite this, the company has launched generic naloxone in 2014 for opioid overdose reversal and generic buprenorphine/naloxone in 2019 for opioid dependence treatment. Viatris supplied medicines to approximately 1 billion patients globally in 2024 , including over 240 medicines on the WHO Essential Medicines List, representing nearly 50% of the total list . The company reached approximately 90% of low- and lower-middle-income countries with its medicines in 2023-2024 , providing ARV treatments for over 24 million adults and children since 2022 . Viatris has eight licensing agreements with the Medicines Patent Pool for HIV, hepatitis C, and COVID-19 , and supports pro-competitive patent settlements to ensure access to generics . The NCD Academy, sponsored by Viatris, has over 30,000 accounts and has impacted approximately 115 million patients through education on non-communicable diseases . Viatris invests in healthcare professional education globally, including reaching nearly 2,000 healthcare professionals in Malaysia via WhatsApp Connect WACR in 2024 . The company conducts clinical trials ethically, adhering to international guidelines and promoting diversity in trial populations . Viatris also committed to reducing absolute scope 1 and 2 greenhouse gas emissions by 42% by 2030 from a 2020 base year , having achieved a 3.7% reduction since 2020 .

Fair Money & Economic Opportunity

Viatris Inc. operates within the healthcare industry, focusing on generics and specialty drugs.

The company does not engage in direct financial services or microloans. While its efforts to make medications accessible can indirectly reduce economic inequality, this value specifically assesses direct financial activities. Therefore, all KPIs related to financial services are not applicable.

Fair Pay & Worker Respect

Viatris reported a total recordable incident rate (TRIR) of 0.50 in 2023, which is significantly lower than the industry average of 1.6.

The company implements various safety initiatives, including safety walks, process safety reviews for new products, and risk assessments. Viatris announced plans to lay off 1,431 employees, with severance pay of 2 weeks per year of service, up to a maximum of 52 weeks and a minimum of 12 weeks. Health care, including COBRA premiums, will be subsidized for the severance period for impacted employees. An FDA warning letter was issued in December 2024 following a June 2024 inspection of Viatris' Pithampur plant in India, citing significant data integrity issues where analysts documented testing results without being physically present. Viatris fired several senior staffers responsible for these violations. The FDA recommended engaging a consultant and conducting interviews of current and former employees to identify the root cause of data inaccuracies. Viatris is also under investigation for potential misconduct regarding disclosure delays about the FDA inspection.

Fair Trade & Ethical Sourcing

No incidents of forced or child labor were reported.

The company monitors supplier alignment to its Supplier Code, which prohibits such practices, through engagement and assessment programs. External audits of suppliers, contractors, and service providers are conducted on a cycle of every two to five years.

Honest & Fair Business

Viatris faces significant ESG controversies, including a December 2024 FDA warning letter and import alert for non-compliance with Current Good Manufacturing Practices at its Indore facility

. This non-compliance is projected to negatively impact 2025 revenues by $500 million and adjusted EBITDA by $385 million . The company is also subject to ongoing investigations by Hagens Berman regarding potential delayed disclosure to investors and by law firms concerning potential securities fraud . Despite these issues, Viatris was recognized in 3BL's 100 Best Corporate Citizens of 2023 for its commitment to ethical business practices and transparency .

Kind to Animals

Viatris states it does not conduct animal testing unless required by national regulations

and is committed to the '3R' approach (Replacement, Reduction, and Refinement) for ethical animal testing . The company conducts pre-clinical studies on animals to assess drug safety . Facilities performing animal testing on Viatris' behalf are required to comply with regional scientific procedures and/or be approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) . In 2024, the Global Operations Audit team audited eight AAALAC-certified facilities , following 12 such audits in 2022 . However, Viatris has not disclosed specific efforts to reduce or replace animal testing .

No War, No Weapons

Viatris Inc. is a global healthcare company focused on pharmaceuticals and explicitly states it does not manufacture weapons, military goods, or components, with its business model inherently avoiding direct involvement with military manufacturing or sales.

A $32.9 million contract from the U.S. Department of Veterans Affairs was for pharmaceuticals, not arms. Viatris is a signatory to the UN Global Compact and committed to its ten principles related to human rights, labor, environment, and anti-corruption. In 2024, Viatris provided $1 million to agencies supporting healthcare, food security, and water stewardship, which represents approximately 0.0068% of its $14.7 billion total revenue.

Planet-Friendly Business

Viatris' Scope 1 and 2 greenhouse gas emissions reduction target of 42% and Scope 3 emissions reduction target of 25% by 2030 have been validated by the Science Based Targets initiative.

The company was recognized as one of America’s Climate Leaders 2023 for significant reductions in emissions intensity. In 2022, Viatris reduced water withdrawal by 7% and increased its zero-waste landfill locations to 16. Packaging reduction efforts in 2023 included a 90 metric ton reduction in paper and a 2 metric ton reduction in plastic. All manufacturing sites in Ireland use 100% renewable electricity, and a solar system in Australia generates 158,000 kWh annually. The company also enhances energy efficiency by transitioning refrigeration units and upgrading HVAC systems, and optimizes supply chain emissions by reducing reliance on air freight and focusing on full truck loads.

Respect for Cultures & Communities

Viatris reported that 97% of its global colleagues engaged in Diversity, Equity, and Inclusion (DEI) learning by the end of 2023

, with programs and Employee Resource Groups reflecting a commitment to cultural sensitivity and inclusion. The company has no reported cultural appropriation incidents. Viatris provides a Compliance Line as a standard mechanism for reporting concerns. In 2023, Viatris provided over $1 million in corporate philanthropy donations to humanitarian relief partners.

Safe & Smart Tech

Viatris outlines user rights for personal data, including access, correction, deletion, objection, restriction, and data transfer, with processes designed to comply with GDPR and other data protection requirements

. The company maintains vulnerability and patch management , utilizing third-party managed security providers for vulnerability assessment . Regarding data minimization, Viatris states it retains personal data only for as long as necessary for its collected purposes or as required by applicable laws . In terms of regulatory compliance, Viatris reports adherence to various statutory and regulatory requirements, such as the FDA’s Drug Supply Chain Security Act (DSCSA) ahead of its deadline and the UK's Windsor Framework . However, the company has one open FDA Warning Letter for Current Good Manufacturing Practice (CGMP) violations at its Indore, India facility , leading to an import alert for 11 products as of December 19, 2024 .

Zero Waste & Sustainable Products

Viatris reported a waste diversion rate of 53% in 2024, achieved through recycling, reclamation, and reuse.

The company has implemented numerous waste reduction initiatives, including repurposing over 230 tons of waste at its Indore facility and 50 tons at Jadcherla in 2023. Sludge paddle dryers at Nashik and Indore facilities contributed to an 80% reduction in waste sent to landfill in 2023 compared to the previous year. In 2024, approximately 349,000 kL of wastewater was recovered and reused in India through zero-liquid discharge systems, and over 1100 kL of rainwater was collected and reused at the Carole Park facility in Australia. Viatris has a company-wide target to increase the number of zero landfill locations by 50% by 2030 from a 2020 baseline. In 2023, the company reported no material fines or non-monetary sanctions for non-compliance with environmental laws and/or regulations.